Identification of a novel CYP2C19-mediated metabolic pathway of S-citalopram in vitro

Drug Metabolism and Disposition

Volumn 37, Issue 12, 2009, Pages 2340-2348

  Rudberg, Ida ^a   Reubsaet, J L E ^b   Hermann, M ^a   Refsum, H ^a   Molden, E ^a,b  

^a DIAKONHJEMMET HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C19; ESCITALOPRAM; NORCITALOPRAM;

ARTICLE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME KINETICS; GENOTYPE; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ARYL HYDROCARBON HYDROXYLASES; BIOTRANSFORMATION; CITALOPRAM; DEALKYLATION; FEMALE; GENOTYPE; HUMANS; KINETICS; MALE; MICROSOMES; MIDDLE AGED; MODELS, BIOLOGICAL; PHENOTYPE; PROPIONIC ACIDS; RECOMBINANT PROTEINS; SEROTONIN UPTAKE INHIBITORS;

EID: 71049179025     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.109.029355     Document Type: Article

References (32)

1. Baumann P, Nil R, Souche A, Montaldi S, Baettig D, Lambert S, Uehlinger C, Kasas A, Amey M, and Jonzier-Perey M (1996) A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: a clinical, pharmacokinetic, and pharmacogenetic investigation. J Clin Psychopharmacol 16:307-314. (Pubitemid 26254882)
2. Bondolfi G, Chautems C, Rochat B, Bertschy G, and Baumann P (1996) Non-response to citalopram in depressive patients: pharmacokinetic and clinical consequences of a fluvoxamine augmentation. Psychopharmacology 128:421-425. (Pubitemid 26417684)
3. Bondolfi G, Lissner C, Kosel M, Eap CB, and Baumann P (2000) Fluoxetine augmentation in citalopram non-responders: pharmacokinetic and clinical consequences. Int J Neuropsychopharmacol 3:55-60. (Pubitemid 30354453)
4. Dalgaard L and Larsen C (1999) Metabolism and excretion of citalopram in man: identification of O-acyl- and N-glucuronides. Xenobiotica 29:1033-1041. (Pubitemid 29515923)
5. Herrlin K, Yasui-Furukori N, Tybring G, Widén J, Gustafsson LL, and Bertilsson L (2003) Metabolism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of healthy Swedes. Br J Clin Pharmacol 56:415-421. (Pubitemid 37188136)
6. Houston JB and Kenworthy KE (2000) In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model. Drug Metab Dispos 28:246-254.
7. Hyttel J, Bøgesø KP, Perregaard J, and Sánchez C (1992) The pharmacological effect of citalopram residues in the (S)-(+)-enantiomer. J Neural Transm Gen Sect 88:157-160.
8. Kobayashi K, Chiba K, Yagi T, Shimada N, Taniguchi T, Horie T, Tani M, Yamamoto T, Ishizaki T, and Kuroiwa Y (1997) Identification of cytochrome P450 isoforms involved in citalopram N-demethylation by human liver microsomes. J Pharmacol Exp Ther 280:927-933. (Pubitemid 27171357)
9. Kosel M, Amey M, Aubert AC, and Baumann P (2001) In vitro metabolism of citalopram by monoamine oxidase B in human blood. Eur Neuropsychopharmacol 11:75-78. (Pubitemid 32162505)
10. Kosel M, Gnerre C, Voirol P, Amey M, Rochat B, Bouras C, Testa B, and Baumann P (2002) In vitro biotransformation of the selective serotonin reuptake inhibitor citalopram, its enantiomers and demethylated metabolites by monoamine oxidase in rat and human brain preparations. Mol Psychiatry 7:181-188. (Pubitemid 34177786)
11. Motulsky HJ and Christopoulos A (2003) Comparing models, in Fitting Models to Biological Data Using Linear and Nonlinear Regression - A Practical Guide to Curve Fitting, pp 134-159, GraphPad Software Inc., San Diego, CA.
12. Nath A and Atkins WM (2006) A theoretical validation of the substrate depletion approach to determining kinetic parameters. Drug Metab Dispos 34:1433-1435. (Pubitemid 44285381)
13. Nikisch G, Mathé AA, Czernik A, Eap CB, Jiménez-Vasquez P, Brawand-Amey M, and Baumann P (2004) Stereoselective metabolism of citalopram in plasma and cerebrospinal fluid of depressive patients: relationship with 5-HIAA in CSF and clinical response. J Clin Psychopharmacol 24:283-290. (Pubitemid 38658036)
14. Olesen OV and Linnet K (1999) Studies on the stereoselective metabolism of citalopram by human liver microsomes and cDNA-expressed cytochrome P450 enzymes. Pharmacology 59:298-309.
15. Oyehaug E, Ostensen ET, and Salvesen B (1984) High-performance liquid chromatographic determination of citalopram and four of its metabolites in plasma and urine samples from psychiatric patients. J Chromatogr 308:199-208. (Pubitemid 14121770)
16. Rochat B, Amey M, and Baumann P (1995a) Analysis of enantiomers of citalopram and its demethylated metabolites in plasma of depressive patients using chiral reverse-phase liquid chromatography. Ther Drug Monit 17:273-279.
17. Rochat B, Amey M, Gillet M, Meyer UA, and Baumann P (1997) Identification of three cytochrome P450 isozymes involved in N-demethylation of citalopram enantiomers in human liver microsomes. Pharmacogenetics 7:1-10. (Pubitemid 27153314)
18. Rochat B, Amey M, Van Gelderen H, Testa B, and Baumann P (1995b) Determination of the enantiomers of citalopram, its demethylated and propionic acid metabolites in human plasma by chiral HPLC. Chirality 7:389-395.
19. Rochat B, Kosel M, Boss G, Testa B, Gillet M, and Baumann P (1998) Stereoselective biotransformation of the selective serotonin reuptake inhibitor citalopram and its demethylated metabolites by monoamine oxidases in human liver. Biochem Pharmacol 56:15-23. (Pubitemid 28477447)
20. Rudberg I, Hendset M, Uthus LH, Molden E, and Refsum H (2006) Heterozygous mutation in CYP2C19 significantly increases the concentration/dose ratio of racemic citalopram and escitalopram (S-citalopram). Ther Drug Monit 28:102-105. (Pubitemid 44391702)
21. Rudberg I, Mohebi B, Hermann M, Refsum H, and Molden E (2008) Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients. Clin Pharmacol Ther 83:322-327.
22. Sidhu J, Priskorn M, Poulsen M, Segonzac A, Grollier G, and Larsen F (1997) Steady-state pharmacokinetics of the enantiomers of citalopram and its metabolites in humans. Chirality 9:686-692. (Pubitemid 27479378)
23. Sindrup SH, Brøsen K, Hansen MG, Aaes-Jørgensen T, Overø KF, and Gram LF (1993) Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. Ther Drug Monit 15:11-17.
24. Sladek NE, Manthey CL, Maki PA, Zhang Z, and Landkamer GJ (1989) Xenobiotic oxidation catalyzed by aldehyde dehydrogenases. Drug Metab Rev 20:697-720. (Pubitemid 19277728)
25. Testa B and Krämer SD (2007) The biochemistry of drug metabolism - an introduction: Part 2. Redox reactions and their enzymes. Chem Biodivers 4:257-405.
26. Tracy TS and Hummel MA (2004) Modeling kinetic data from in vitro drug metabolism enzyme experiments. Drug Metab Rev 36:231-242.
27. Venkatakrishnan K, Von Moltke LL, and Greenblatt DJ (2001) Human drug metabolism and the cytochromes P450: application and relevance of in vitro models. J Clin Pharmacol 41:1149-1179. (Pubitemid 32983216)
28. Voirol P, Rubin C, Bryois C, Kosel M, Buclin T, and Baumann P (1999) Pharmacokinetic consequences of a citalopram treatment discontinuation. Ther Drug Monit 21:263-266. (Pubitemid 29249514)
29. von Moltke LL, Greenblatt DJ, Giancarlo GM, Granda BW, Harmatz JS, and Shader RI (2001) Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram. Drug Metab Dispos 29:1102-1109.
30. Watanabe K, Narimatsu S, Yamamoto I, and Yoshimura H (1990) Hepatic microsomal oxygenation of aldehydes to carboxylic acids. Biochem Biophys Res Commun 166:1308-1312. (Pubitemid 20068982)
31. Yu BN, Chen GL, He N, Ouyang DS, Chen XP, Liu ZQ, and Zhou HH (2003) Pharmacokinetics of citalopram in relation to genetic polymorphism of CYP2C19. Drug Metab Dispos 31:1255-1259. (Pubitemid 37152977)
32. Zhang QY, Dunbar D, and Kaminsky L (2000) Human cytochrome P-450 metabolism of retinals to retinoic acids. Drug Metab Dispos 28:292-297. (Pubitemid 30137053)